Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis

European Journal of Pharmacology

Volumn 691, Issue 1-3, 2012, Pages 9-18

  Dal Rhee, Sang ^a   Kim, Chi Hyun ^a   Seon Park, Ji ^a   Hoon Jung, Won ^a   Bum Park, Sung ^a,b   Youn Kim, Hee ^a   Hwan Bae, Gyu ^a   Jan Kim, Ta ^a   Young Kim, Ki ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Apoptosis; Fatty liver; Inflammation; Reactive oxygen species; Sterol regulatory element binding protein 1c

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARBENOXOLONE; CYTOCHROME C; CYTOKINE; FATTY ACID; FATTY ACID SYNTHASE; LIVER X RECEPTOR; OLEIC ACID; PALMITIC ACID; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; C57BL 6 MOUSE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FATTY ACID BLOOD LEVEL; FATTY LIVER; HUMAN; HUMAN CELL; LIPOGENESIS; LIVER INJURY; LIVER PROTECTION; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOPTOSIS; CARBENOXOLONE; CYTOKINES; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84865025248     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.06.021     Document Type: Article

References (31)

1. P. Alberts, L. Engblom, N. Edling, M. Forsgren, G. Klingström, C. Larsson, Y. Rönquist-Nii, B. Ohman, and L. Abrahmsén Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice Diabetologia 45 2002 1528 1532 (Pubitemid 35352046)
2. P. Angulo Treatment of nonalcoholic fatty liver disease Ann. Hepatol. 1 2002 12 19
3. J.D. Browning, and J.D. Horton Molecular mediators of hepatic steatosis and liver injury J. Clin. Invest. 114 2004 147 152 (Pubitemid 39071617)
4. I.J. Bujalska, L.L. Gathercole, J.W. Tomlinson, C. Darimont, J. Ermolieff, A.N. Fanjul, P.A. Rejto, and P.M. Stewart A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis J. Endocrinol. 197 2008 297 307 (Pubitemid 351696242)
5. L.M. Cagen, X. Deng, H.G. Wilcox, E.A. Park, R. Raghow, and M.B. Elam Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements Biochem. J. 385 2005 207 216
6. C. Carter-Kent, N.N. Zein, and A.E. Feldstein Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment Am. J. Gastroenterol. 10 2008 1036 1042 (Pubitemid 351501089)
7. C.P. Day Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 50 2002 585 588 (Pubitemid 34407478)
8. X. Deng, C. Yellaturu, L. Cagen, H.G. Wilcox, E.A. Park, R. Raghow, and M.B. Elam Expression of the rat sterol regulatory element-binding protein-1c gene in response to insulin is mediated by increased transactivating capacity of specificity protein 1 (Sp1) J. Biol. Chem. 282 2007 17517 17529 (Pubitemid 47100272)
9. C. García-Ruiz, A. Colell, A. Morales, N. Kaplowitz, and J.C. Fernández-Checa Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes Mol. Pharmacol. 48 1995 825 834
10. M.J. Gómez-Lechón, M.T. Donato, A. Martínez-Romero, N. Jiménez, J.V. Castell, and J.E. OConnor A human hepatocellular in vitro model to investigate steatosis Chem. Biol. Interact. 165 2007 106 116 (Pubitemid 46072796)
11. J.L. Halaas, K.S. Gajiwala, M. Maffei, S.L. Cohen, B.T. Chait, D. Rabinowitz, R.L. Lallone, S.K. Burley, and J.M. Friedman Weight-reducing effects of the plasma protein encoded by the obese gene Science 269 1995 543 546
12. K. Hensley, Y. Kotake, H. Sang, Q.N. Pye, G.L. Wallis, L.M. Kolker, T. Tabatabaie, C.A. Stewart, Y. Konishi, D. Nakae, and R.A. Floyd Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria Carcinogenesis 21 2000 983 989 (Pubitemid 30265144)
13. J.D. Horton Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis Biochem. Soc. Trans. 30 2002 1091 1095 (Pubitemid 36002414)
14. F. Laubenthal Carbenoxolone as a possible cause of liver damage Dtsch. Med. Wochenschr. 97 36 1972 1351 1354
15. C.S. Lieber The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role Drug Metab. Rev. 36 2004 511 529 (Pubitemid 39453060)
16. J. Liu, X. Jin, C.H. Yu, S.H. Chen, W.P. Li, and Y.M. Li Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis J. Gastroenterol. Hepatol. 25 2010 613 618
17. Y. Liu, Y. Nakagawa, Y. Wang, L. Liu, H. Du, W. Wang, X. Ren, K. Lutfy, and T.C. Friedman Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice J. Mol. Endocrinol. 41 2008 53 64
18. Y. Liu, F. Park, J.L. Pietrusz, G. Jia, R.J. Singh, B.C. Netzel, and M. Liang Suppression of 11beta-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis Physiol. Genomics. 32 2008 343 351 (Pubitemid 351328557)
19. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier A transgenic model of visceral obesity and the metabolic syndrome Science 294 2001 2166 2170 (Pubitemid 33150673)
20. S.A. Morgan, and J.W. Tomlinson 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes Expert. Opin. Investig. Drugs 19 2010 1067 1076
21. A.M. Nuotio-Antar, D.L. Hachey, and A.H. Hasty Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice Am. J. Physiol. Endocrinol. Metab. 293 2007 E1517 E1528
22. J.S. Park, S.D. Rhee, N.S. Kang, W.H. Jung, H.Y. Kim, J.H. Kim, S.K. Kang, H.G. Cheon, J.H. Ahn, and K.Y. Kim Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2 H-1,2-benzothiazine-2-yl-1- phenylethanone (KR-66344) Biochem. Pharmacol. 81 2011 1028 1035
23. K.G. Park, A.K. Min, E.H. Koh, H.S. Kim, M.O. Kim, H.S. Park, Y.D. Kim, T.S. Yoon, B.K. Jang, J.S. Hwang, J.B. Kim, H.S. Choi, J.Y. Park, I.K. Lee, and K.U. Lee Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways Hepatology 48 2008 1477 1486
24. L.S. Pivato, R.P. Constantin, E.L. Ishii-Iwamoto, A.M. Kelmer-Bracht, N.S. Yamamoto, J Constantin, and A. Bracht Metabolic effects of carbenoxolone in rat liver J. Biochem. Mol. Toxicol. 20 5 2006 230 240 (Pubitemid 44569559)
25. C. Postic, and J. Girard The role of the lipogenic pathway in the development of hepatic steatosis Diabetes Metab. 34 2008 643 648
26. M. Salvi, C. Fiore, V. Battaglia, M. Palermo, D. Armanini, and A. Toninello Carbenoxolone induces oxidative stress in liver mitochondria, which is responsible for transition pore opening Endocrinology 146 2005 2306 2312 (Pubitemid 40577518)
27. J.M. Schroeder-Gloeckler, S.M. Rahman, R.C. Janssen, L. Qiao, J. Shao, M. Roper, S.J. Fischer, E. Lowe, D.J. Orlicky, J.L. McManaman, C. Palmer, W.L. Gitomer, W. Huang, R.M. ODoherty, T.C. Becker, D.J. Klemm, D.R. Jensen, L.K. Pulawa, R.H. Eckel, and J.E. Friedman CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice J. Biol. Chem. 282 2007 15717 15729 (Pubitemid 47093283)
28. A. Taylor, N. Irwin, A.M. McKillop, P.R. Flatt, and V.A. Gault Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity Biol. Chem. 389 2008 441 445 (Pubitemid 351773918)
29. J.W. Tomlinson, O.M. Durrani, I.J. Bujalska, L.L. Gathercole, P.J. Tomlins, T.T. Reuser, G.E. Rose, S.J. Curnow, P.M. Stewart, E.A. Walker, and S. Rauz The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy J. Clin. Endocrinol. Metab. 95 2010 398 406
30. K.Z. Xu, C. Zhu, M.S. Kim, J. Yamahara, and Y. Li Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity J. Ethnopharmacol. 123 2 2009 280 287
31. N. Yahagi, H. Shimano, A.H. Hasty, T. Matsuzaka, T. Ide, T. Yoshikawa, M. Amemiya-Kudo, S. Tomita, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, J. Osuga, K. Harada, T. Gotoda, R. Nagai, S. Ishibashi, and N. Yamada Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice J. Biol. Chem. 277 2002 19353 19357 (Pubitemid 34967441)